Morten Ruhwald, MD, PhD joins NIVI Development from FIND, the global alliance for diagnostics based in Geneva, where he served as Director of the Tuberculosis Programme.
Over the past six years, Morten Ruhwald has been at the forefront of global efforts to innovate and improve TB diagnostics. Under his leadership, FIND forged critical partnerships with industry, academia, national programs, and global health institutions — helping to reshape the TB diagnostics pipeline and position new tools for real-world impact. Prior to joining FIND, Morten was responsible for the clinical development of vaccine candidates as well as the human immunology program at the Center for Vaccine Research at Statens Serum Institut, Denmark.
A physician-scientist by training, Morten brings over 15 years of experience bridging science, clinical development, and public health policy.
At NIVI Development, he will oversee clinical development programs and play a central role in driving scientific and translational strategy. He will help ensure that NIVI’s innovations – from early-stage vaccine platforms to late-stage clinical vaccine interventions – are designed with end-users in mind and meet the highest standards of safety, efficacy, and impact.